Denis Babkov, Vice-Rector for Research at Volgograd State Medical University, announced that university scientists have developed a new capsule-based drug for treating type 2 diabetes and obesity, and have begun clinical trials.
Hot Topics
Trump rejected a Saudi request to launch US strikes against the Houthis
First successful robot-assisted double liver and kidney transplant in the United States
A prominent historian In Israel a large number of lions and lionesses are led by donkeys
Babkov says: "The drug 'Depyarone' comes in capsule form to treat type 2 diabetes, metabolic syndrome, and obesity, and it works through a new mechanism. For example, unlike the drug Ozempic, which mimics the action of the GLP-1 hormone, Depyarone, through its effect on the GPR119 receptor, stimulates the production of the body's natural hormones, which helps regulate blood sugar levels. It has shown in animal experiments its ability to preserve and regenerate the pancreatic cells responsible for producing insulin."
The inventors point out that scientists in various countries had previously attempted to develop a drug with a similar mechanism of action, but encountered problems related to the active ingredient entering the bloodstream, causing side effects. However, the university scientists were able to create a drug that works directly in the intestines, with virtually no bloodstream penetration and no adverse effects.
One of the advantages of the innovative drug compared to similar drugs is that it will be available in capsule form, while other drugs for treating diabetes and obesity are produced by injection, which is not always suitable for patients.
According to him, laboratory tests showed no toxic effects of the drug Dipyarone on liver or heart cells. These results indicate the drug's safety. However, a definitive assessment of the drug's safety can only be made through clinical trials in humans.
He says: "The first phase of preclinical testing has been completed, and in July, approval was granted to conduct the second phase, which includes 308 patients with type 2 diabetes. This phase involves determining how effective the drug is at lowering blood sugar levels in humans, and what the most effective doses are."
what is your opinion on this news ?do let us know in the comments on tha comment box
if you liked this news article please share on friends & family & don't forget to follow on website & social media